Skip to main content

Ciclopirox (Monograph)

Brand names: Loprox, Penlac Nail Lacquer
Drug class: Hydroxypyridones
Chemical name: 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone compound with 2-aminoethanol (1:1)
Molecular formula: C12H17NO2βC2H7NO
CAS number: 41621-49-2

Medically reviewed by Drugs.com on Jun 21, 2023. Written by ASHP.

Introduction

Antifungal;1 2 3 chemically unrelated to imidazoles or other antifungal agents currently available in US.4

Uses for Ciclopirox

Dermatophytoses and Cutaneous Candidiasis

Treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton mentagrophytes, T. rubrum, Epidermophyton floccosum, or Microsporum canis.1 25 27 31 66

Efficacy in the treatment of plantar and vesicular types of tinea pedis not established.28 Oral antifungal agent usually necessary for the treatment of hyperkeratotic areas on palms and soles or chronic moccasin-type tinea pedis.31 32 36

Oral antifungal agents preferred when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised or has coexisting disease.31 32 35 36 37

Treatment of cutaneous candidiasis caused by Candida albicans.1 66

Pityriasis (Tinea) Versicolor

Treatment of pityriasis (tinea) versicolor caused by Malassezia furfur (Pityrosporum orbiculare or P. ovale).1 25 66

Oral antifungal agents preferred in patients who have extensive or severe infections or who fail to respond to or have frequent relapses with topical therapy.33 34 36

Seborrheic Dermatitis

Treatment of seborrheic dermatitis of the scalp.28 65

Has not been studied in immunocompromised patients (e.g., HIV or transplant patients),28 65 patients with a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses; recent or recurring herpes zoster; persistent herpes simplex), 65 or those with diabetic neuropathy.65

Onychomycosis

Treatment of mild to moderate onychomycosis of fingernails and toenails, without lunula involvement, caused by T. rubrum in immunocompetent patients.40 43 45 49 56 57 58 59 60

Oral antifungal therapy usually preferred for extensive (e.g., >30%) nail involvement.46

Has not been studied in immunocompromised individuals (e.g., those with insulin-dependent diabetes, diabetic neuropathy, severe plantar/moccasin-type tinea pedis, HIV infection, or solid organ transplantation).40

Ciclopirox Dosage and Administration

Administration

Topical Administration

Apply topically to the skin as a cream,1 gel,28 lotion,66 or shampoo65 and to nails as a solution (nail lacquer).40

Do not apply to the eye1 25 28 40 65 66 or administer orally or intravaginally.23 24 40 65 Avoid contact with mucous membranes.28 40 65

Cream, Gel, or Lotion

Apply a sufficient amount of cream, gel, or lotion in the morning and evening; rub gently into cleansed, affected area and surrounding skin.1 23 25 31 66

Do not use with occlusive dressings or wrappings.1 28 66

Shampoo

If contact with eye(s) occurs, rinse thoroughly with water.65

Solution (Nail Lacquer)

Use in conjunction with frequent (e.g., monthly) appointments with a qualified clinician in nail disorders and weekly self-trimming of infected nail(s).40

Remove any loose nail or nail material (using nail clippers or nail files) before initiating therapy.40

Apply solution evenly over entire nail bed, undersurface of nail plate (if free of nail bed), and 5 mm of surrounding skin using applicator brush provided by the manufacturer.40

Avoid contact with skin other than that immediately surrounding the treated nail(s) (because of risk of adverse dermatologic reactions).40

After applying solution, wait ≥8 hours before bathing.40

Allow nail(s) to dry (about 30 seconds) before wearing socks or stockings.40

Do not apply nail polish or other cosmetic nail products on treated nail(s).40

Dosage

Available as ciclopirox and ciclopirox olamine; dosage expressed in terms of ciclopirox.1 28 40 65 66

Pediatric Patients

Dermatophytoses and Cutaneous Candidiasis
Topical

Children ≥10 years of age: Apply 0.77% cream or lotion twice daily.1 23 25 31 66

If clinical improvement does not occur after 4 weeks of treatment, reevaluate the diagnosis.1 25 66

Pityriasis (Tinea) Versicolor
Topical

Children ≥10 years of age: Apply 0.77% cream or lotion twice daily.1 23 25 31 66

Clinical improvement usually occurs after 2 weeks of treatment.1 25 66

Adults

Dermatophytoses and Cutaneous Candidiasis
Topical

Apply 0.77% cream or lotion twice daily.1 23 25 31 66 Alternatively, in the treatment of interdigital tinea pedis or tinea corporis, apply 0.77% gel twice daily.28

If clinical improvement does not occur after 4 weeks of treatment, reevaluate the diagnosis.1 25 66

Pityriasis (Tinea) Versicolor
Topical

Apply 0.77% cream or lotion twice daily.1 23 25 31 66

Clinical improvement usually occurs after 2 weeks of treatment.1 25 66

Seborrheic Dermatitis
Topical

Apply 0.77% gel to affected areas twice daily.28

Alternatively, apply approximately 5 mL (10 mL for long hair) of 1% shampoo to wet hair and scalp and lather.65 Allow drug to remain on the scalp for 3 minutes and then rinse.65 Repeat treatment twice weekly for 4 weeks, with a minimum of 3 days between applications.65

If clinical improvement does not occur after 4 weeks of treatment, reevaluate the diagnosis.65

Onychomycosis
Topical

Apply 8% topical solution (nail lacquer) once daily (preferably at bedtime).40 Remove accumulated applications of the drug with alcohol every 7 days; daily removal of solution is not recommended.40

Initial improvement of symptoms may require 6 months of therapy and up to 48 weeks of continuous comprehensive therapy to achieve clear or almost clear nail(s).40

Detailed Ciclopirox topical dosage information

Cautions for Ciclopirox

Contraindications

Warnings/Precautions

Sensitivity Reactions

If irritation or sensitivation occurs, discontinue the drug and initiate appropriate therapy.1 25 40 66

General Precautions

Local Effects

Possible pruritus, transient burning sensation, and/or pain at the site of application.1 28 40 66

Specific Populations

Pregnancy

Category B.1 28 65 66

Lactation

Not known whether ciclopirox is distributed into milk.1 28 40 65 66 Use with caution in nursing women.1 25 28 40 65 66

Pediatric Use

Safety and efficacy of topical ciclopirox solution (nail lacquer) not established in children.40

Safety and efficacy of topical ciclopirox olamine preparations (i.e., cream, lotion) and topical ciclopirox gel not established in children ≤10 and 16 years of age, respectively.1 28 66

Insufficient experience with ciclopirox shampoo in children ≤16 years of age to determine whether pediatric patients respond differently than adults.65

Geriatric Use

No substantial differences in safety and efficacy of ciclopirox topical solution (nail lacquer) relative to younger adults.40

No substantial differences in safety of ciclopirox shampoo relative to younger adults.65 Insufficient experience in patients ≥65 years of age to determine whether efficacy in geriatric patients is different from that in younger adults.65

Race

Insufficient experience in black patients to determine whether they respond differently to ciclopirox shampoo than other races.65

Common Adverse Effects

Local burning sensation or pain; mild, transient erythema.1 28 40 66

Drug Interactions

Systemic Antifungal Agents

No studies conducted in patients with onychomycosis to determine whether topical ciclopirox solution might reduce efficacy of systemic antifungals; combined use of the topical solution with a systemic antifungal agent is not recommended.40

Ciclopirox Pharmacokinetics

Absorption

Percutaneous absorption appears to be rapid but minimal following topical application to intact skin.11 40

Penetration of drug following topical application of 0.77% lotion is equivalent to that of 0.77% cream.25 27

Systemic absorption of 0.77% gel is higher than that of 0.77% cream.28

Distribution

Extent

Penetrates into hair and nail40 and is absorbed through the epidermis and hair follicles into sebaceous glands and dermis, while a portion remains in the stratum corneum.1 11 25 66

Crosses the placenta in very small amounts in animals.11

Plasma Protein Binding

Approximately 94–98%.11

Elimination

Metabolism

Almost completely conjugated with glucuronic acid;11 about 1–2% of the drug appears to be metabolized to N-desoxyciclopirox and another unidentified metabolite.11

Elimination Route

Excreted rapidly and almost completely in urine;11 25 negligible fecal excretion.1 11 25 66

Half-life

Biologic half-life of approximately 1.7 hours following application of 0.77% cream or lotion.1 11 25 66

Renal elimination half-life of approximately 5.5 hours following application of 0.77% gel.28

Stability

Storage

Topical

Cream, Gel, or Shampoo

15–30°C.1 28 65

Lotion

5–25°C.66

Solution

15–30°C.40 Keep away from heat and flame.40

Actions and Spectrum

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Ciclopirox

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Topical

Gel

0.77%

Loprox (with isopropyl alcohol)

Medicis

Shampoo

1%

Loprox

Medicis

Solution

8%

Penlac Nail Lacquer (with isopropyl alcohol)

Dermik
Ciclopirox Olamine

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Topical

Cream

0.77% (of ciclopirox)

Loprox (with benzyl alcohol 1%)

Medicis

Lotion

0.77% (of ciclopirox)

Loprox (with benzyl alcohol 1%)

Medicis

AHFS DI Essentials™. © Copyright 2024, Selected Revisions July 1, 2005. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

1. Medicis Pharmaceutical Corp. Loprox (ciclopirox olamine) cream 0.77% prescribing information. Scottsdale, AZ; 2002 Oct.

2. Hoechst-Roussel Pharmaceuticals, Inc. Pharmacy and therapeutics committee report: Loprox (ciclopirox olamine) cream 1%. Somerville, NJ; 1983 Mar.

3. Dittmar W, Druckey E, Urbach H. Quantitative structure-activity analysis in a series of antimycotically active N-hydroxypyridones. J Med Chem. 1974; 17:753-6. http://www.ncbi.nlm.nih.gov/pubmed/4836409?dopt=AbstractPlus

4. Anon. New topical antifungal drugs. Med Lett Drugs Ther. 1983; 25:98-100. http://www.ncbi.nlm.nih.gov/pubmed/6621505?dopt=AbstractPlus

5. Reynolds JEF, ed. Martindale: the extra pharmacopeia. 28th ed. London: The Pharmaceutical Press; 1982:720.

6. Sakurai K, Sakaguchi T, Yamaguchi H et al. Mode of action of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt (Hoe 296). Chemotherapy. 1978; 24:68-76. http://www.ncbi.nlm.nih.gov/pubmed/340169?dopt=AbstractPlus

7. Iwata VK, Yamaguchi H. Studies on the mechanism of antifungal action of ciclopiroxolamine: inhibition of transmembrane transport of amino acid, K+ and phosphate in Candida albicans cells. (German) Arzneim-Forsch. 1981; 31:1323-7.

8. Dittmar W, Lohaus G. HOE 296, a new antimycotic compound with a broad antimicrobial spectrum. (German) Arzneim-Forsch. 1973; 23:670-4.

9. Dittmar W, Grau W, Raether W et al. Microbiological laboratory studies with ciclopiroxolamine. (German) Arzneim-Forsch. 1981; 31:1317-22.

10. Sakurai K, Sakaguchi T, Yamaguchi H et al. Antimicrobial activity of Hoe 296, a new synthetic antifungal agent. I. In vitro antimicrobial activity and curative effect against experimental Trichophyton mentagrophytes infection. (Japanese) Jpn J Med Mycol. 1975; 16:35-40.

11. Kellner, HM, Arnold C, Christ OE et al. Studies on pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topic and systemic application. (German) Arzneim-Forsch. 1981; 31:1337-53.

12. Dittmar W. Penetration and antifungal activity of ciclopiroxolamine in hornified tissue. (German) Arzneim-Forsch. 1981; 31:1353-9.

13. Adam, VW, Peil HG, Savopoulos C et al. Clinical results with the antimycotic agent ciclopiroxolamine. (German) Arzneim-Forsch. 1981; 31:1360-8.

14. Fredriksson T, Savopoulos C. Comparative double-blind study on ciclopiroxolamine cream and placebo cream in dermatophytoses. (German) Arzneim-Forsch. 1981; 31:1376-8.

15. Dittmar VW. Non-European open clinical studies on the efficacy and tolerance of ciclopiroxolamine in dermatomycoses. (German) Arzneim-Forsch. 1981; 31:1381-5.

16. Hoechst-Roussel Pharmaceuticals, Inc. Loprox (ciclopiroxolamine) cream 1% effectiveness and safety. Somerville, NJ; 1983.

17. Torres VJ, Savopoulos C, Dittmar W. Open clinical trial in dermal mycoses of a 1% ciclopiroxolamine solution in polyethylene glycol 400 carried out in FR Germany/Study with shortened therapy. (German) Arzneim-Forsch. 1981; 31:1373-6.

18. Beyer M. Selected double-blind comparative studies on the efficacy and tolerance of ciclopiroxolamine solution and cream. (German) Arzneim-Forsch. 1981; 31:1378-81.

19. Anon. Drugs for athlete’s foot and tinea cruris. Med Lett Drugs Ther. 1976; 18:101-2. http://www.ncbi.nlm.nih.gov/pubmed/1036605?dopt=AbstractPlus

20. Qadripur SA, Horn G, Hohler T. On the local efficacy of ciclopiroxolamine in onychomycoses. (German) Arzneim-Forsch. 1981; 31:1369-72.

21. Sehgal VN. Ciclopirox: a new topical pyrodonium antimycotic agent. A double-blind study in superficial dermatomycoses. Br J Dermatol. 1976; 95:83-8. http://www.ncbi.nlm.nih.gov/pubmed/782504?dopt=AbstractPlus

22. Peil VHG. Open clinical study on the efficacy and tolerance of ciclopiroxolamine in vulvovaginal candidosis. (German) Arzneim-Forsch. 1981; 31:1366-8.

23. Roney JV (Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ): Personal communication; 1984 Mar 12.

24. Reviewers’ comments (personal observations); 1984 Mar 20.

25. Hoechst-Roussel Pharmaceuticals, Inc. Loprox (ciclopirox olamine) lotion 1% prescribing information (dated 1995 Mar). In Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998:1221-2.

26. Hoechst-Roussel Pharmaceuticals, Inc. Pharmacy and therapeutics committee report supplement: Loprox (ciclopirox olamine) lotion 1%. Somerville, NJ; 1989 Apr.

27. Aly R, Maibach HI, Bagatell FK et al. Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis. Clin Ther. 1989; 11:290-303. http://www.ncbi.nlm.nih.gov/pubmed/2663159?dopt=AbstractPlus

28. Medicis Pharmaceutical Corp. Loprox (ciclopirox) gel 0.77%. prescribing information. Scottsdale, AZ; 2002 Mar.

29. Hänel H, Smith-Kurtz E, Pastowsky S. Treatment of seborrhoic eczema using an antimycotic with antiphlogistic properties. (German; with English abstract.) Mycoses. 1991; 34 (Suppl):91-3.

30. Schmidt A. Malassezia furfur: a fungus belonging to the physiological skin flora and its relevance in skin disorders. Cutis. 1997; 59:21-4. http://www.ncbi.nlm.nih.gov/pubmed/9013067?dopt=AbstractPlus

31. Gupta AK, Einarson TR, Summerbell RC et al. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs. 1998; 55:645-74. http://www.ncbi.nlm.nih.gov/pubmed/9585862?dopt=AbstractPlus

32. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs. 1996; 52:209-24. http://www.ncbi.nlm.nih.gov/pubmed/8841739?dopt=AbstractPlus

33. Sunenshine PJ, Schwartz RA, Janniger CK. Tinea versicolor: an update. Cutis. 1998; 61:65-72. http://www.ncbi.nlm.nih.gov/pubmed/9515210?dopt=AbstractPlus

34. Assaf RR, Weil ML. The superficial mycoses. Dermatol Clin. 1996; 14:57-67. http://www.ncbi.nlm.nih.gov/pubmed/8821158?dopt=AbstractPlus

35. Lesher JL. Recent developments in antifungal therapy. Dermatol Clin. 1996; 14:163-9. http://www.ncbi.nlm.nih.gov/pubmed/8821170?dopt=AbstractPlus

36. Hay RJ. Dermatophytosis and other superficial mycoses. In: Mandel GL, Douglas RG Jr, Bennett JE, eds. Principles and practices of infectious disease. 4th ed. New York: Churchill Livingston; 1995: 2375-86.

37. Drake LA, Dincehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol. 1996; 34:282-6. http://www.ncbi.nlm.nih.gov/pubmed/8642094?dopt=AbstractPlus

38. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. J Am Acad Dermatol. 1996; 34:287-9. http://www.ncbi.nlm.nih.gov/pubmed/8642095?dopt=AbstractPlus

39. Reviewers’ comments (personal observations) on Sulconazole 84:04.08.

40. Dermik Laboratories. Penlac (ciclopirox) 8% topical solution prescribing information. Berwyn, PA; 2003 Jun.

41. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer solution 8% in the treatment of onychomycosis. J Am Acad Dermatol. 2000; (Suppl):S57-69. http://www.ncbi.nlm.nih.gov/pubmed/11051135?dopt=AbstractPlus

42. Janssen Pharmaceutica. Sporanox (itraconazole) capsules prescribing information (dated 2000 Jan). In: Physicians’ desk reference. 55th ed. Montvale, NJ: Medical Economics Company Inc; 2001:1584-7.

43. Gupta AK, Baran R. Ciclopirox nail lacquerl solution 8% in the 21st century. J Am Acad Dermatol. 2000; 43(Suppl):S86-102.

44. Novartis Pharmaceuticals. Lamisil (terbinafine hydrochloride) tablets prescribing information (dated 1999 Nov). In: Physicians’ desk reference. 55th ed. Montvale, NJ: Medical Economics Company Inc; 2001:2179-81.

45. Anon. Ciclopirox (Penlac) nail lacquer for onychomycosis. Med Lett Drugs Ther. 2000; 42:51-2. http://www.ncbi.nlm.nih.gov/pubmed/10859733?dopt=AbstractPlus

46. Niewerth M, Korting HC. Management of onychomycoses. Drugs. 1999; 58:283-96. http://www.ncbi.nlm.nih.gov/pubmed/10473020?dopt=AbstractPlus

47. Rodgers P, Bassler M. Treating onychomycosis. Am Fam Physician. 2001; 63:663-72, 677-8. http://www.ncbi.nlm.nih.gov/pubmed/11237081?dopt=AbstractPlus

48. Reisberger EM, Szeimies RM. Therapy of onychomicosis. (German; with English abstract.) Med Klin. 2000; 95:618-28.

49. Gupta AK. Onychomycosis in the elderly. Drugs Aging. 2000; 16:397-407. http://www.ncbi.nlm.nih.gov/pubmed/10939306?dopt=AbstractPlus

50. Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol. 1999; 141(Suppl 56):1-4. http://www.ncbi.nlm.nih.gov/pubmed/10730907?dopt=AbstractPlus

51. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs. 1992; 43:259-84. http://www.ncbi.nlm.nih.gov/pubmed/1372222?dopt=AbstractPlus

52. Brodell RT, Elewski BE. Clinical Pearl: Systemic antifungal drugs and drug interactions. J Am Acad Dermatol. 1995; 33:259-260. http://www.ncbi.nlm.nih.gov/pubmed/7622654?dopt=AbstractPlus

53. Anon. Terbinafine for onychomycosis. Med Lett Drugs Ther. 1996; 38:72-4. http://www.ncbi.nlm.nih.gov/pubmed/8699988?dopt=AbstractPlus

54. Dupin N, Gorin I, Djien V et al. Acute generalized exanthematous pustulosis induced by terbinafine. Arch Dermatol. 1996; 132:1253-4. http://www.ncbi.nlm.nih.gov/pubmed/8859047?dopt=AbstractPlus

55. Odom RB. New therapies for onychomycosis. J Am Acad Dermatol. 1996; 35:S26-30. http://www.ncbi.nlm.nih.gov/pubmed/8784308?dopt=AbstractPlus

56. Gupta AK, Malkin K. Ciclopirox nail lacquer and podiatric practice. J Am Podiatr Med Assoc. 2000; 90:502-7. http://www.ncbi.nlm.nih.gov/pubmed/11107711?dopt=AbstractPlus

57. Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J Am Podiatr Med Assoc. 2000; 90:495-501. http://www.ncbi.nlm.nih.gov/pubmed/11107710?dopt=AbstractPlus

58. Gupta AK. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol. 2000; 43(Suppl 4):S81-95.

59. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000; 43(Suppl 4):S70-80.

60. Gupta AK. Ciclopirox nail lacquer topical solution 8%. Skin Therapy Lett. 2000; 6:1-5. http://www.ncbi.nlm.nih.gov/pubmed/11027420?dopt=AbstractPlus

61. Baran R, Feuilhade M, Datry A et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol. 2000; 42:1177-83.

62. Bonifaz A, Ibarra G. Onychomycosis in children: treatment with bifonazole-urea. Pediatr Dermatol. 2000; 17:310-4. http://www.ncbi.nlm.nih.gov/pubmed/10990584?dopt=AbstractPlus

63. Tsuboi R, Unno K, Komatsuzaki H et al. [Topical treatment of onychomycosis by occlusive dressing using bifonazole cream containing 40% urea.] (Japanese with English abstract.) Nippon Ishinkin Gakkai Zasshi. 1998; 39:11-6.

64. Friedman-Birnbaum R, Cohen A, Shemer A et al. Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. Int J Dermatol. 1997; 36:67-9. http://www.ncbi.nlm.nih.gov/pubmed/9071624?dopt=AbstractPlus

65. Medicis Pharmaceutical Corp. Loprox (ciclopirox) shampoo 1% prescribing information. Scottsdale, AZ; 2003 Feb.

66. Medicis Pharmaceutical Corp. Loprox (ciclopirox olamine) lotion 0.77% prescribing information. Scottsdale, AZ; 2002 Feb.

Frequently asked questions

Medical Disclaimer